Table 2.
Relationship between miR-99a expression and their clinicopathological parameters in 47 EC patients
| Clinicopathological parameters | Number of cases | Expression of miR-99a | P-value |
|---|---|---|---|
| Age (years) | |||
| ≥60 | 32 | 2.441±1.714 | 0.5164 |
| <60 | 15 | 2.107±1.443 | |
| FIGO stage | |||
| Stage I+II | 34 | 2.650±1.354 | 0.0297* |
| Stage III+IV | 13 | 1.509±2.014 | |
| Grade | |||
| G1+G2 | 36 | 2.656±1.715 | 0.0126* |
| G3 | 11 | 1.284±0.509 | |
| Myometrial invasion | |||
| <1/2 myometrialthickenss | 23 | 2.442±1.928 | 0.6626 |
| >1/2 myometrialthickenss | 24 | 2.232±1.304 | |
| Lymph node metastasis | |||
| No | 30 | 2.513±1.857 | 0.3232 |
| Yes | 17 | 2.020±1.084 |
Abbreviations: P-value represents the probability from a Student’s t-test for miR-99a expression between variable subgroups.
*
P<0.05 was considered to have a significant difference.